Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

1EORTC 18071, 20151E1609 (ipi10), 20201CheckMate 238, 20171E1609 (ipi3), 2020interferon alpha vs. Ipilimumab (10 mg/kg) 1.14 [0.89; 1.45]1.14 [0.89;1.45]interferon alpha vs. Ipilimumab (10 mg/kg) 1.14 [0.89; 1.45]interferon alpha vs. ipilimumab alone ipilimumab alone better 1.28 [1.01; 1.63]1.28 [1.01;1.63]interferon alpha vs. ipilimumab alone ipilimumab alone better 1.28 [1.01; 1.63]interferon alpha vs. nivolumab alone 1.31 [0.91; 1.88]1.31 [0.91;1.88]interferon alpha vs. nivolumab alone 1.31 [0.91; 1.88]interferon alpha vs. placebo 0.82 [0.59; 1.13]0.82 [0.59;1.13]interferon alpha vs. placebo 0.82 [0.59; 1.13]Ipilimumab (10 mg/kg) vs. interferon alpha 0.88 [0.69; 1.12]0.88 [0.69;1.12]Ipilimumab (10 mg/kg) vs. interferon alpha 0.88 [0.69; 1.12]Ipilimumab (10 mg/kg) vs. ipilimumab alone 1.13 [0.80; 1.59]1.13 [0.80;1.59]Ipilimumab (10 mg/kg) vs. ipilimumab alone 1.13 [0.80; 1.59]Ipilimumab (10 mg/kg) vs. nivolumab alone 1.15 [0.87; 1.51]1.15 [0.87;1.51]Ipilimumab (10 mg/kg) vs. nivolumab alone 1.15 [0.87; 1.51]Ipilimumab (10 mg/kg) vs. placebo Ipilimumab (10 mg/kg) better 0.72 [0.58; 0.89]0.72 [0.58;0.89]Ipilimumab (10 mg/kg) vs. placebo Ipilimumab (10 mg/kg) better 0.72 [0.58; 0.89]ipilimumab alone vs. interferon alpha ipilimumab alone better 0.78 [0.61; 0.99]0.78 [0.61;0.99]ipilimumab alone vs. interferon alpha ipilimumab alone better 0.78 [0.61; 0.99]ipilimumab alone vs. Ipilimumab (10 mg/kg) 0.89 [0.63; 1.25]0.89 [0.63;1.25]ipilimumab alone vs. Ipilimumab (10 mg/kg) 0.89 [0.63; 1.25]ipilimumab alone vs. nivolumab alone 1.02 [0.66; 1.58]1.02 [0.66;1.58]ipilimumab alone vs. nivolumab alone 1.02 [0.66; 1.58]ipilimumab alone vs. placebo ipilimumab alone better 0.64 [0.43; 0.95]0.64 [0.43;0.95]ipilimumab alone vs. placebo ipilimumab alone better 0.64 [0.43; 0.95]nivolumab alone vs. interferon alpha 0.77 [0.53; 1.10]0.77 [0.53;1.10]nivolumab alone vs. interferon alpha 0.77 [0.53; 1.10]nivolumab alone vs. Ipilimumab (10 mg/kg) 0.87 [0.66; 1.14]0.87 [0.66;1.14]nivolumab alone vs. Ipilimumab (10 mg/kg) 0.87 [0.66; 1.14]nivolumab alone vs. ipilimumab alone 0.98 [0.63; 1.52]0.98 [0.63;1.52]nivolumab alone vs. ipilimumab alone 0.98 [0.63; 1.52]nivolumab alone vs. placebo nivolumab alone better 0.63 [0.44; 0.88]0.63 [0.44;0.88]nivolumab alone vs. placebo nivolumab alone better 0.63 [0.44; 0.88]placebo vs. interferon alpha 1.22 [0.89; 1.68]1.22 [0.89;1.68]placebo vs. interferon alpha 1.22 [0.89; 1.68]placebo vs. Ipilimumab (10 mg/kg) Ipilimumab (10 mg/kg) better 1.39 [1.13; 1.71]1.39 [1.13;1.71]placebo vs. Ipilimumab (10 mg/kg) Ipilimumab (10 mg/kg) better 1.39 [1.13; 1.71]placebo vs. ipilimumab alone ipilimumab alone better 1.57 [1.05; 2.34]1.57 [1.05;2.34]placebo vs. ipilimumab alone ipilimumab alone better 1.57 [1.05; 2.34]placebo vs. nivolumab alone nivolumab alone better 1.60 [1.13; 2.25]1.60 [1.13;2.25]placebo vs. nivolumab alone nivolumab alone better 1.60 [1.13; 2.25]Ipilimumab (10 mg/kg)placebonivolumab aloneinterferon alphapembrolizumab alonenivolumab plus ipilimumabipilimumab alonedirect evidencenetwork meta-analysis
T vs. C Ipilimumab (10 mg/kg)placebonivolumab aloneinterferon alphapembrolizumab alonenivolumab plus ipilimumabipilimumab alone
Ipilimumab (10 mg/kg)---0.72
0.58; 0.89		1.15
0.87; 1.51		0.88
0.69; 1.12		NANA1.13
0.80; 1.59
placebo1.39
1.13; 1.71		---1.60
1.13; 2.25		1.22
0.89; 1.68		NANA1.57
1.05; 2.34
nivolumab alone0.87
0.66; 1.14		0.63
0.44; 0.88		---0.77
0.53; 1.10		NANA0.98
0.63; 1.52
interferon alpha1.14
0.89; 1.45		0.82
0.59; 1.13		1.31
0.91; 1.88		---NANA1.28
1.01; 1.63
pembrolizumab aloneNANANANA---NANA
nivolumab plus ipilimumabNANANANANA---NA
ipilimumab alone0.89
0.63; 1.25		0.64
0.43; 0.95		1.02
0.66; 1.58		0.78
0.61; 0.99		NANA---

pathologies: 70 - treatments: 329,558 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons